Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hanneke K. A. Knaapen"'
Autor:
Wieneke M. T. van den Hombergh, Brigit E. Kersten, Hanneke K. A. Knaapen-Hans, Rogier M. Thurlings, Peter M. van der Kraan, Frank H. J. van den Hoogen, Jaap Fransen, Madelon C. Vonk
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-6 (2018)
Abstract Background Mounting evidence indicates that inflammatory mechanisms drive systemic sclerosis (SSc) vasculopathy and fibrosis, especially early in the disease. Therefore, patients with very early SSc could benefit from early treatments target
Externí odkaz:
https://doaj.org/article/cd5efa835f0d48b0afa128f57869c572
Autor:
Frank H J van den Hoogen, Håvard Fretheim, Anna-Maria Hoffmann-Vold, Hanneke K. A. Knaapen, Cornelia Hm van den Ende, Jolanda van Haren-Willems, Anthony L Duijnhouwer, Madelon C. Vonk, Arie P.J. van Dijk, Jacqueline Mj Lemmers
Objective: To describe the efficacy and safety in all patients with systemic sclerosis–associated pulmonary arterial hypertension who started selexipag between 09-2016 and 06-2018 in two pulmonary arterial hypertension expert centers. Methods: All
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b56d9fe6e7a6bdb104ff515400f0bab7
http://hdl.handle.net/10852/82283
http://hdl.handle.net/10852/82283
Autor:
Jolanda van Haren-Willems, C.H.M. van den Ende, Madelon C. Vonk, Anna-Maria Hoffmann-Vold, Toon Duijnhouwer, Jacqueline Mj Lemmers, Frank J. A. van den Hoogen, Håvard Fretheim, Arie P.J. van Dijk, Hanneke K. A. Knaapen-Hans
Publikováno v:
Saturday, 15 June 2019.
Background Pulmonary arterial hypertension (PAH) is a frequent complication in systemic sclerosis (SSc) and a major cause of death despite the available treatments (1). Until the availability of the oral prostacyclin receptor agonist selexipag in 201
Autor:
Jaap Fransen, Patricia Carreira, Hanneke K. A. Knaapen-Hans, Wieneke M. T. van den Hombergh, Madelon C. Vonk, Frank H J van den Hoogen
Publikováno v:
Rheumatology, 55, 11, pp. 2023-2032
Rheumatology, 55, 2023-2032
Rheumatology, 55, 2023-2032
Contains fulltext : 171205.pdf (Publisher’s version ) (Closed access) OBJECTIVE: DcSSc is associated with high morbidity related to widespread skin disease and poor prognosis due to earlier and more severe organ involvement. The objective of this s
Autor:
Hanneke K. A. Knaapen-Hans, Madelon C. Vonk, Frank H J van den Hoogen, Pim Kranenburg, Jaap Fransen, Wieneke M. T. van den Hombergh
Publikováno v:
Rheumatology, 55, 11, pp. 2001-2008
Rheumatology, 55, 2001-2008
Rheumatology, 55, 2001-2008
Contains fulltext : 171578.pdf (Publisher’s version ) (Closed access) OBJECTIVE: LcSSc is associated with ACAs and a mild course, whereas dcSSc is associated with anti-topoisomerase antibodies (ATAs) and a more severe course. However, ATAs are also
Autor:
W. Van Den Hombergh, Madelon C. Vonk, F.H.J. van den Hoogen, Jaap Fransen, Hanneke K. A. Knaapen
Publikováno v:
Abstracts Accepted for Publication.
Background Systemic sclerosis (SSc) patients are at risk for organ involvement and premature death. The occurrence of organ involvement that is reported differs widely between various long term cohort studies; ILD 25–90%, PAH 8–32%, CI 5–30%, a
Autor:
S. O. Simons, Hanneke K. A. Knaapen, J. Fransen, W. Van Den Hombergh, F.H.J. van den Hoogen, Madelon C. Vonk
Publikováno v:
Abstracts Accepted for Publication.
Background The pathogenesis of interstitial lung disease associated with systemic sclerosis (SSc-ILD) is not completely elucidated, although it is believed that chronic alveolar inflammation leads to increasing fibrosis. Treatment strategies using cy
Autor:
Wim B. van den Berg, Willem A. Dik, Hanneke K. A. Knaapen, Virgil A. S. H. Dalm, Adriana Severino, Naomi I Maria, Lenny van Bon, Marjan A. Versnel, Zana Brkic, Lorenzo Beretta, Madelon C. Vonk, Paul L A van Daele, Cornelia G van Helden-Meeuwsen, Timothy R D J Radstake, Samara Guillen, Marta Cossu
Publikováno v:
Annals of the Rheumatic Diseases, 75, 8, pp. 1567-73
Annals of the Rheumatic Diseases, 75, 1567-73
Annals of the Rheumatic Diseases, 75(8), 1567-1573. BMJ Publishing Group
Annals of the Rheumatic Diseases, 75, 1567-73
Annals of the Rheumatic Diseases, 75(8), 1567-1573. BMJ Publishing Group
Contains fulltext : 171751.pdf (Publisher’s version ) (Closed access) BACKGROUND: Interferon (IFN) signature has been reported in definite systemic sclerosis (SSc) but it has not been characterised in early SSc (EaSSc). We aim at characterising IFN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb695ab6410125769f9f96922756034
https://doi.org/10.1136/annrheumdis-2015-207392
https://doi.org/10.1136/annrheumdis-2015-207392
Autor:
Hanneke K. A. Knaapen, Jorre S. Mertens, Timothy R D J Radstake, Esther P A H Hoppenreijs, Peter C.M. van de Kerkhof, Diane Marsman, Elke M G J de Jong, Marieke M B Seyger
Publikováno v:
Acta Dermato-Venereologica, 96, 4, pp. 510-3
Acta Dermato-Venereologica, 96, 510-3
Acta Dermato-Venereologica, 96(4), 510. Society for the Publication of Acta Dermato-Venereologica
Acta Dermato-Venereologica, 96, 510-3
Acta Dermato-Venereologica, 96(4), 510. Society for the Publication of Acta Dermato-Venereologica
Contains fulltext : 168598.pdf (Publisher’s version ) (Open Access) To assess the efficacy and safety of mycophenolate mofetil (MMF) in patients with localized scleroderma (LoS) resistant or intolerant to previous treatment with methotrexate (MTX).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56620ed9a2030655d41e913ac2c1f70a
https://doi.org/10.2340/00015555-2297
https://doi.org/10.2340/00015555-2297
Autor:
Piet L. C. M. van Riel, Hanneke K. A. Knaapen, Martin Lammens, Madelon C. Vonk, Kavish J. Bhansing, Baziel G.M. van Engelen
Publikováno v:
Arthritis research and therapy
Arthritis Research & Therapy
Arthritis Research & Therapy, 16, R111
Arthritis Research & Therapy, 16, 3, pp. R111
Arthritis Research & Therapy
Arthritis Research & Therapy, 16, R111
Arthritis Research & Therapy, 16, 3, pp. R111
Contains fulltext : 136771.pdf (Publisher’s version ) (Open Access) INTRODUCTION: The objective was to characterize the clinical and myopathologic features of patients with scleroderma-polymyositis (SSc-PM) overlap compared with a population of pat